Milestone Reached in Alzheimer's Disease Vaccine

A new trial aims to evaluate the tolerability and safety of an innovative Alzheimer's vaccine (Affitope AD01). Utilizing newly developed technology, scientists are now creating molecules with very specific binding characteristics and molecules that differ in structure but exhibit identical binding characteristics, in this instance, to safely protect the brain cells and only combat the disease-causing the beta-amyloid responsible for Alzheimer's.

AFFiRiS has announced the successful completion of patient recruitment for clinical phase I testing of its Alzheimer's vaccine AD01. The vaccine is being administered at the Vienna General Hospital (AKH) to 24 Alzheimer's patients, at a mild to moderate stage of the disease. The patients are being vaccinated four times over a three-month period. During this time, and over a further two months, the safety and tolerability of the vaccine is being investigated. A professional care network with the highest medical standards ensures the patients' health and well-being.

All patients have been vaccinated at least once and so far tolerated the vaccine extremely well. The treatment provides for four vaccinations administered at monthly intervals and is due to be completed by October 2008. The vaccine's tolerability can then be conclusively evaluated. So far, the results indicate good tolerability for this Alzheimer's vaccine from AFFiRiS, GmbH (Vienna, Austria; www.affiris.com). It is on this basis that recruitment of further patients has already begun for the clinical trial of a second Alzheimer's vaccine by AFFiRiS.

Commenting on the planned progression of the trial, Dr. Walter Schmidt, CEO of AFFiRiS said, "We have now treated the maximum number of patients for the first time. After the end of the trial in a few months' time, we will know whether the impression so far of our vaccine's good tolerability is confirmed. As patient interest in the last few months has grown significantly, we are delighted that we are already in a position to offer participation in clinical testing of our second Alzheimer's vaccine, Affitope AD02.”

The Alzheimer's vaccines developed by AFFiRiS are based on Affitome technology developed in-house, which functions using the mimotope principle. This technology enables the development of customized vaccines known as Affitope. Dr. Schmidt explained the special features of AFFiRiS's approach to the Alzheimer's vaccine, "Alzheimer's is caused by beta-amyloid, an unwanted fragment of one of the body's own proteins that occurs on the surface of brain cells. Development of a successful vaccine is extremely challenging, as it is vital to ensure that antibodies only attack beta-amyloid if it occurs separated in the brain fluid but not as long as it is still part of the normal APP protein on the brain cells. The brain cells would otherwise be attacked. Thanks to Affitome technology, we are in the unique position of being able to safely protect the brain cells and only combat the disease-causing beta-amyloid.”

Affitome technology patented by the company enables scientists to create both molecules with very specific binding characteristics and molecules that differ in structure but exhibit identical binding characteristics. These strengths are now being used in developing the AD01 and AD02 vaccines, both of which align the immune system against the same beta-amyloid structure. However, Affitome technology can also be used to have a positive influence on other human rogue proteins, such as lipid metabolism enzymes. Consequently, an appropriate development by AFFiRiS could provide an effective treatment for atherosclerosis.

AFFiRiS develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis, and other diseases that urgently require a medical solution. The company has established platform technologies and registered the corresponding patent families. The first patents have already been issued.

Related Links:
AFFiRiS